ÌÇÐÄÆƽâ°æ

Potential savings due to biosimilars for 8 key products combined in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)*

© ÌÇÐÄÆƽâ°æ 2026
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

September 2016

Region

United States, EU

Survey time period

as of December 2015

Supplementary notes

* Savings potential in EU5+US biosimilar accessible market dependent on change in price per treatment day. The accessible market analysis is based on Adalimumab, Insulin glargine, Etanercept, Infliximiab, Rituximab, Peg-filgrastim, Trastuzumab and Follitropin alpha. Savings potential in biosimilar accessible market at different price levels is calculated based on extrapolated size of the originator market between 2016 and 2020 based on historic CAGR and analogues. Accumulation of savings potential between 2016-2020 is shown.
EU-5 includes Germany, UK, France, Italy, and Spain.

Citation formats

Potential biosimilars savings in EU5 countries and the U.S. 2016-2020

Published by ÌÇÐÄÆƽâ°æ Research Department, Apr 13, 2017
This statistic shows the potential cumulative savings due to the introduction of biosimilars for * key products combined in EU-5 countries and the U.S. between 2016 and 2020. Until 2017, assuming a price reduction of ** percent for the * key products' biosimilars, savings would reach around * billion U.S. dollars.
Log in or register to access precise data.
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

  • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 99 users
Talk to sales for pricing
Contact us
  • Free + Premium Statistics
  • Reports
  • Market ÌÇÐÄÆƽâ°æ

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Other statistics that may interest you

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Statistics on

About the industry

10

About the region

10

Selected statistics

10

Other regions

10

Related statistics

10

Further Content: You might find this interesting as well

Topics

Generics and biosimilars in ItalyTop pharmaceutical drugsHealth and food supplements market in ItalyNon-prescription drugs in ItalyPharmaceutical market in Italy
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

  • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 99 users
Talk to sales for pricing
Contact us
  • Free + Premium Statistics
  • Reports
  • Market ÌÇÐÄÆƽâ°æ

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.